Drug: The drug under study acts on TRPC4 ion channels and represents a completely new potential option for the treatment of a number of mental disorders and migraine headaches.
Method of administration: The drug is taken in tablet form.
Duration and design of the study: Patients will receive a study drug or placebo for 2 months.
Why participate in the survey?
Therapeutic options in patients with PTSD are limited to the use of antidepressants from the group of SSRI inhibitors and anxiolytics, so there is a great need to discover a new drug. Great contribution to the clinical experience with a completely new group of drugs in psychiatry. The effectiveness of the treatment will be monitored by a team of three top psychiatric specialists.
Persons who are potential candidates for participation:
- Men and women aged 18-65 years.
- Diagnosed with PTSD at any time in the past.
- Moderate or severe disease (> 33 points according to the PCL-5 questionnaire).
- Patients can take all other types of PTSD medication if the dose is stable over the last 2 months.
Persons NOT candidates for participation in the survey:
- Parallel diagnosis of schizophrenia, psychotic episodes or bipolar disorder.
- Addiction to alcohol or other psychoactive substances.
Start of patient involvement: May 2022.
Completion of inclusion of patients in the study: Until the quota is filled